Bill Hinshaw, Axcella CEO

Say­ing good­bye to R&D chief, Flag­ship-backed Ax­cel­la drops PhII pro­gram as it fo­cus­es on long Covid, NASH

In its bid to be one of the first biotechs to de­vel­op a drug for long Covid, which im­pacts as many as

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.